ConductScience.org, home

Comparison · NCT04104646-646a556e

CHF6563 vs Morphine: Relapse of NOWS

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. CHF6563 vs Morphine: Relapse of NOWS. Trial comparisons, record NCT04104646-646a556e. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04104646-646a556e

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.20.03620.624wilson
Risk in group 2000.658wilson
Risk difference, group 1 minus group 20.2-0.4780.624newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to treat, for one more participant with the outcome on CHF6563 than on Morphine5from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1CHF6563Sublingual dose of CHF6563 and the corresponding oral dose of morphine matched placebo15OG000
Group 2MorphineOral dose of morphine and the corresponding sublingual dose of CHF6563 matched placebo02OG001

Outcome

Type
SECONDARY
Title
Relapse of NOWS
Description
Relapse of NOWS, defined as experiencing recurrence of significant signs of withdrawal .~Reported are subjects with experiencing a relapse.~The number of subjects randomised in the study was much lower than planned. No imputation of missing or incomplete data was made. No statistical analysis was performed.~NOWS=Neonatal Opioid Withdrawal Syndrome
Time frame
up to 6 weeks after last dose
Population
Randomised Set: All randomised subjects. Only 7 subjects were randomised into the study; 2 subjects completed the study as planned; therefore, no statistical analysis was performed.~Due to low recruitment rate, the study was terminated early for non-safety reasons.

Source ClinicalTrials.gov

Trial

Title
CHF6563 in Babies With Neonatal Opioid Withdrawal Syndrome
NCT number
NCT04104646
Phases
PHASE2
Conditions
Neonatal Opioid Withdrawal Syndrome
Interventions
CHF6563, Morphine, CHF6563 matched placebo, Morphine matched placebo
Lead sponsor
Chiesi Farmaceutici S.p.A.
Results first posted
2023-08-03

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT04104646-646a556e